Ultragenyx Pharmaceutical Inc. (RARE) Financials
RARE Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 1.3 billion | 1.5 billion |
| March 31, 2026 | 1.3 billion | 1.5 billion |
| Dec. 31, 2025 | 1.5 billion | 1.6 billion |
| Sept. 30, 2025 | 1.2 billion | 1.2 billion |
RARE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -98.0 million | 34.0 million |
| March 31, 2026 | -198.0 million | 30.0 million |
| Dec. 31, 2025 | -100.8 million | 37.3 million |
| Sept. 30, 2025 | -92.7 million | 37.0 million |
RARE Net Income
No data available :(
RARE Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 292.0 million | - | - |
| March 31, 2026 | 413.0 million | 1.1 billion | - |
| Dec. 31, 2025 | 693.0 million | 1.2 billion | 24.0 million |
| Sept. 30, 2025 | 435.1 million | 785.4 million | 33.8 million |
RARE Shares Outstanding
RARE Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 1.0 million | 167.0 million | 88.0 million | - |
| March 31, 2026 | 1.0 million | 187.0 million | 88.0 million | - |
| Dec. 31, 2025 | 938000 | 203.0 million | 89.0 million | - |
| Sept. 30, 2025 | 1.3 million | 216.2 million | 86.6 million | - |
RARE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 214.0 million | 34.0 million |
| March 31, 2026 | 136.0 million | 30.0 million |
| Dec. 31, 2025 | 207.0 million | 29.0 million |
| Sept. 30, 2025 | 159.9 million | 28.0 million |
RARE Revenue by Segment
Graph available only for paid members. Upgrade to see it.
RARE
Price: $26.49
52 week price:
Payout Ratio Range:
Earnings Per Share: -6.03 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 449700
Ebitda: -96.8 millionMarket Capitalization: 2.6 billion